HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

dicyclohexyl 2,3-epoxysuccinate (Ep-1)

thiol protease inhibitor; RN given refers to (trans)-isomer

Also Known As:

Ep-1; trans-dicyclohexyl 2,3-epoxysuccinate

Networked: 21 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Alicyclic Hydrocarbons: 1
      - Cycloparaffins: 6
        Cyclohexanes: 3
        dicyclohexyl 2,3-epoxysuccinate: 21

Experts

1.	Liu, Ming: 3 articles (11/2022 - 12/2007)
2.	Zhang, Zhibin: 3 articles (11/2022 - 12/2007)
3.	Wang, Mingxing: 3 articles (06/2019 - 01/2017)
4.	Hinds, Lyn A: 2 articles (11/2022 - 12/2007)
5.	Li, Hongjun: 2 articles (11/2022 - 10/2019)
6.	Wang, Dandan: 2 articles (06/2019 - 03/2019)
7.	Zhao, Daqing: 2 articles (06/2019 - 03/2019)
8.	Zhang, Yanqiu: 2 articles (03/2019 - 01/2017)
9.	Chang, Gang: 1 article (11/2022)
10.	Chen, Xiaoning: 1 article (11/2022)

Related Diseases

1.	Hypersensitivity (Allergy) 03/01/1984 - "The in vivo administration of Ep-1 caused a depression of the plaque forming cells (PFC) for sheep red blood cell (SRBC) and enhanced the delayed-type hypersensitivity (DTH) for bovine serum albumin (BSA) as well as mixed lymphocytes cultures (MLC). " 01/01/2003 - "The attenuation of secondary esophageal hyperalgesia by ZD6416 suggests that PGE(2), via the EP-1 receptor, contributes to human visceral pain hypersensitivity." 01/01/2003 - "The purpose of this study was to determine whether acid-induced pain hypersensitivity within the non-acid-exposed esophagus (secondary hyperalgesia) is mediated by PGE(2) activation of the EP-1 receptor. "
2.	Pain (Aches) 01/01/2003 - "The purpose of this study was to determine whether acid-induced pain hypersensitivity within the non-acid-exposed esophagus (secondary hyperalgesia) is mediated by PGE(2) activation of the EP-1 receptor. "
3.	Hyperalgesia 01/01/2003 - "The attenuation of secondary esophageal hyperalgesia by ZD6416 suggests that PGE(2), via the EP-1 receptor, contributes to human visceral pain hypersensitivity." 01/01/2003 - "The purpose of this study was to determine whether acid-induced pain hypersensitivity within the non-acid-exposed esophagus (secondary hyperalgesia) is mediated by PGE(2) activation of the EP-1 receptor. "
4.	Body Weight (Weight, Body) 10/26/2023 - "Compared to the control group, all animals in EP-1 treatment groups showed significantly decreased food intake and body weight. " 01/01/2020 - "The EP-1 significantly reduced the pups' body weight, the amount and pulse duration of USVs, whereas the frequency range variation of USVs was increased. " 10/01/2019 - "Mice in the three treatment groups were provided one of the three EP-1 mixture compounds for 3 successive days via gavage at a dosage of 50 mg/kg(body weight), and then all mice were sacrificed 15 days after the gavage treatment. " 12/01/2007 - "The doses for EP-1, E and P were 1, 0.34 and 0.66 mg/kg body weight, respectively. "
5.	Ulcerative Colitis 03/15/2019 - "Thus, EP-1 shows potential for the development of new functional foods and drugs, especially in regard to treating ulcerative colitis." 06/01/2019 - "EP-1, a purified unique polysaccharide isolated from HE mycelium, has recently been identified as the active component responsible for anti- ulcerative colitis activity by using a cell model for identification. "

Related Drugs and Biologics

1.	Prostaglandins E
2.	Acids
3.	Polysaccharides (Glycans)
4.	Lactic Acid (Lactate)
5.	Brain-Derived Neurotrophic Factor (BDNF)
6.	Prostaglandin E Receptors (Prostaglandin E Receptor)
7.	NF-kappa B (NF-kB)
8.	Bovine Serum Albumin
9.	Messenger RNA (mRNA)
10.	Immunosorbents